Severe obstetric complications as a manifestation of thrombotic microangiopathy

Abstract

Thrombotic microangiopathy is one of the most serious thrombotic complications characterized by microvascular thrombosis in various organs and accompanied by thrombocytopenia and hemolytic anemia. The term thrombotic microangiopathy has incorporated several nosology, which are characterized by different mechanisms of microvascular thrombosis. Currently thrombotic microangiopathy include thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), heparin-induced thrombocytopenia, HELLP-syndrome. Pregnancy presents one of the key triggers to the development of thrombotic microangiopathy. This fact gives us a significant opportunity to study the pathogenesis of thrombotic microangiopathy in the context of the physiological changes of hemostasis during pregnancy. At the same time the discovery of molecular mechanisms of thrombotic microangiopathy allows for a new research on the field of pathogenesis of thrombotic complications associated with pregnancy, as well as the pathogenesis of so-called placental obstetric complications, including severe preeclampsia, premature detachment of normally situated placenta, septic shock.

Keywords

pregnancy complications gestosis / preeclampsia / premature detachment of the placenta / thrombotic microangiopathy

References

[1] Austin S. K., Starke R. D., Lawrie A. S., Cohen H., Machin S. J., Mackie I. J. The VWF/ADAMTS-13 axis in antiphospholipid syndrome: ADAMTS-13 antibodies and ADAMTS-13 dysfunction. Br. J. Haematol. 2008; 141 (4): 536-44.

[2] Bell W. R., Kickler T. S. Thrombocytopenia in pregnancy. Rheum. Dis. Clin. North Am. 1997; 23 (1): 183-94.

[3] Eerenberg E. S., Levi M. The potential therapeutic benefit of targeting ADAMTS-13 activity. Semin. Thromb. Hemost. 2014; 40 (1): 28-33.

[4] Furlan M. Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Expert. Rev. Ther. 2003; 1 (2): 243-55.

[5] Furlan M., Lammle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract. Res. Clin. Haematol. 2001; 14 (2): 437-54.

[6] George J. N. Thrombotic thrombocytopenic purpura: a syndrome that keeps evolving. J. Clin. Apheresis. 2004; 19 (2): 63-5.

[7] Isler C. M., Barrilleaux P. S., Magann E. F. et al. A prospective, randomized trial comparing the efficacy of dexamethasone and betamethasone for the treatment of antepartum HELLP (hemolysis, elevated liver enzymes, and low platelet count syndrome. Amer. J. Obstet. Gynec. 2001; 184: 1332-9.

[8] Katz V. L., Farmer R., Kuler J. A. Preeclampsia into eclampsia: Towards a new paradigm. Amer. J. Obstet. Gynec. 2000; 182: 1389-94.

[9] Kentouche K., Voigt A., Schleussner E., Schneppenheim R., Budde U., Beck J. F., Stefańska-Windyga E. Windyga J. Pregnancy in Upshaw-Schulman syndrome. Hamostaseologie. 2013; 33 (2): 144-8.

[10] Klonizakis P. ADAMTS-13 metalloprotease abnormalities in systemic lupus erythematosus: is there a correlation with disease status? Lupus. 2013; 22 (5): 443-52.

[11] Knöbl P. N. Treatment of thrombotic microangiopathy with a focus on new treatment options. Hamostaseologie. 2013; 33 (2): 149-59.

[12] Koenig М., Roy М., Baccot S. et al. Thrombotic microangiopathy with liver, gut, and bone infarction (catastrophic antiphospholipid syndrome) associated with HELLP syndrome. Clin. Rheumatol. 2005; 24 (2): 166-8.

[13] Lammle B., Kremer J., Studt J. D. et al. Thrombotic thrombocytopenic purpura. Hematol. J. 2004; 5 (suppl. 3): S6-11.

[14] Lammle R., Hovinga J. A. K., Alberio L. Thrombotic thrombocytopenic purpura. J. Thrombosis and Haemostasis. 2005; 3: 1663-75.

[15] McCrae K. R., Cines D. B. Thrombotic microangiopathy during pregnancy. Seminars in Hematology. 1997; 34 (2): 148-58.

[16] Moake J. L., Rudy C. K., Troll J. H. et al. Unusually large plasma factor VIII: vonWillebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N. Eng. J. Med. 1982; 307: 1432-5.

[17] O'Brien J. M., Barton J. R. Controversies with the diagnosis and management of HELLP syndrome. Clin. Obstet. Gynec. 2005; 48 (2): 460-77.

[18] Pourrat O., Coudroy R., Pierre F. ADAMTS-13 deficiency in severe postpartum HELLP syndrome. Br. J. Haematol. 2013; 163 (3): 409-10.

[19] Raife T., Montgomery R. New aspects in the pathogenesis and threatment of Thrombotic thrombocytopenic purpura and hemolytic uremic synfrome. Rev. Clin. Exp. Hematol. 2001; 5 (3): 536-61.

[20] Rock G. A., Shumak K. H., Buskard N. A. et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N. Engl. J. Med. 1991; 325 (6): 393-7.

[21] Ruggenenti P., Noris M., Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 2001; 60 (3): 831-46.

[22] Schaller M., Studt J. D., Voorberg J., Kremer Hovinga J. A. Acquired thrombotic thrombocytopenic purpura. Development of an autoimmune response. Hamostaseologie. 2013; 33 (2):121-30.

[23] Sibai B. M., Ramadan M. K., Usta I. et al. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Amer. J. Obstet. Gynec. 1993; 169: 1000-6.

[24] Torok T. J., Holman R. C., Chorba T. L. Increasing mortality from thrombotic thrombocytopenic purpura in the United States - analysis of national mortality data, 1968-1991. Am. J. Hematol. 1995; 50: 84-90.

RIGHTS & PERMISSIONS

Makatsaria A.D., Akinshina S.V., Bitsadze V.O., Andreeva M.D.